Revlimid drives Celgene profit beat; raises EPS forecast

(Reuters) - Celgene Corp rode its flagship multiple myeloma drug Revlimid and a rebound in sales of Otezla for psoriasis to a modestly higher-than-expected second-quarter profit and raised its full-year earnings forecast on Thursday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news